Mazdutide
Also called IBI362, LY3305677
Subcutaneous (under the skin)Human study reference
Research reference
Human study
GLORY-1 trial
Once-weekly study injections in separate 4 mg and 6 mg target groups
48 weeks; targets are not starting amounts
GLORY-1, NEJM (2025) ↗When results may show
- When change was measured
- Body-weight endpoints were assessed at weeks 32 and 48. This is months of observation, not a first-month promise.
- When to assess
- 48 weeks; targets are not starting amounts
- Conditions and limitations
- Chinese adults aged 18–75 with obesity or overweight plus a weight-related condition. This primary trial is not a verified current local product label or a complete starter escalation. No starter is inferred from its target groups.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Sources: GLORY-1, NEJM (2025)
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Mazdutide describe 3–9 mg per administration. Descriptive only, not a recommendation.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- GLORY-1, NEJM (2025)This primary trial is not a verified current local product label or a complete starter escalation. No starter is inferred from its target groups.
Next steps
Mazdutide beginner guideOpen Mazdutide planning worksheetEstimate Mazdutide vial costTrack Mazdutide notes